Predictive and prognostic roles of ribonucleotide reductase m1 in pancreatic cancer: A meta-analysis

Abstract

AIM: To evaluate the role of ribonucleotide reductase M1 (RRM1) in predicting the survival of patients with resectable pancreatic cancer who receive gemcitabine adjuvant therapy. METHODS: Cochrane Library, Medline, Science Direct, Springer link, CBM, Cnki, Wan fang and VIP database were searched before December 31, 2014 to collect the articles regarding RRM1 in the treatment of pancreatic cancer. The quality of the included trials was assessed according to the inclusive and exclusive criteria, and the data were extracted and analyzed using Stata12.0 and RevMan 5.2.10 software. RESULTS: A total of eight clinical studies involving 556 pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy were included, including 373 patients with high RRM1 expression and 293 patients with low RRM1 expression. Meta-analysis showed that high RRM1 expression was associated with improved overall survival (OS) of pancreatic cancer patients (HR = 1.56, 95%CI: 1.17-2.07, P < 0.05). High RRM1 expression also was linked to longer disease-free survival (DFS) than low RRM1 expression (HR = 1.47, 95%CI: 0.83-2.62, P < 0.05). CONCLUSION: This Meta-analysis shows that high RRM1 expression may be associated with improved OS and DFS of pancreatic cancer patients treated with adjuvant gemcitabinebased chemotherapy. The detection of RRM1 expression may be a promising biomarker for predicting the prognosis of pancreatic cancer patients treated with gemcitabine.